#5-19E. Navigating the Telehealth Boom: Safety Deficits in Online GLP-1 Prescribing (JAMA, 2026)

Are we sacrificing patient safety for the convenience of online weight loss treatments? In this episode, we examine a recent secret shopper study investigating the telehealth landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Researchers evaluated 49 online platforms and found that nearly 92% issued prescriptions primarily based on asynchronous, self-reported questionnaires with minimal to no direct clinician interaction. The most critical finding reveals a stark bypass of standard clinical safeguards; some platforms issued prescriptions in under five minutes, often neglecting thorough medical histories or necessary physical assessments. While these direct-to-consumer services increase medication access, they simultaneously raise severe concerns regarding inappropriate prescribing and a lack of longitudinal oversight. However, when critically appraising this study, we must note that it relies on a simulated patient profile, which may obscure the true variability of real-world patient experiences and lacks data on subsequent clinical follow-up. For practicing physicians, these insights are crucial; as more patients self-source compounded or branded GLP-1 RAs online, clinicians must remain vigilant during medication reconciliation, proactively identifying potential risks and ensuring comprehensive patient education to mitigate the hazards of fragmented care.

Citation: Chetty AK, Chen AS, Ross JS, Ramachandran R. Online Prescribing of GLP-1 Receptor Agonists. JAMA. 2026.

DOI: 10.1001/jama.2026.9131

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.